Shared chromatin remodeling mutations drive concurrent rhabdomyosarcoma and leukemia in a pediatric patient.

Ji'ou Zhao, Huimin Li, Yongren Wang, Xiaoyan Sun, Yongjun Fang, Yao Xue

Abstract read

In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ji'ou Zhao *Department of Hematology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, 210008, China.

Huimin Li *Department of Hematology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, 210008, China.

Yongren Wang *Department of Hematology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, 210008, China.

Xiaoyan SunDepartment of Hematology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, 210008, China.

Yongjun FangDepartment of Hematology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, 210008, China. fyj322@126.com.

Yao XueDepartment of Hematology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, 210008, China. yxue@njmu.edu.cn.

Funding

Natural Science Foundation of Jiangsu Province BK20211009Research and Practice Innovation Plan for Graduate Students in Jiangsu Province SJCX24_0796Special Fund for Health Science and Technology Development in Nanjing JQX19008

6 · The paper itself

Abstract

The co-occurrence of rhabdomyosarcoma (RMS) and B-cell acute lymphoblastic leukemia (B-ALL) has been rarely reported, and the shared molecular drivers remain unidentified. This case report describes a pediatric patient diagnosed with both malignancies simultaneously. Whole exome sequencing of RMS and B-ALL samples from this patient identified 91 shared somatic mutations. Subsequent principal component analysis (PCA) of the GSE240287, GSE140556, and GSE26713 datasets, combined with cancer driver gene identification using the IntOGen database, revealed five key drivers: ARID1A, CTCF, SUZ12, CREBBP, and ARID2. These genes may collectively drive tumorigenesis in both malignancies through their involvement in chromatin remodeling pathways.

Indexed as

Chromatin remodelingLeukemiaRhabdomyosarcomaWhole exome sequencing

Identifiers

PMID40522594

DOI10.1007/s12672-025-02967-5

PMCPMC12170473

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.